Stocks dropped after Donald Trump ordered that U.S. companies find alternatives to their operations in China.US Marketsread more
Trump said he was ordering "our great American companies" to "immediately start looking for an alternative to China, including bringing your companies HOME and making your...Politicsread more
President Donald Trump on Friday again ripped into Federal Reserve Chairman Jerome Powell, comparing him to Chinese President Xi Jinping.Politicsread more
Powell repeats his pledge to keep the economic expansion going while acknowledging that tariffs and other factors are causing growth to slow.The Fedread more
China says the new tariffs will begin Sept. 1 and Dec. 15. That's when President Trump's latest tariffs on Chinese goods are to take effect.Marketsread more
The Koch brothers financed one of the most influential political networks in the modern era. The sprawling political empire includes conservative and libertarian nonprofits...Politicsread more
On Tuesday, Walmart filed suit against Tesla alleging its solar panels had caused fires in seven of its stores.Technologyread more
Amazon shows numerous listings for toys and medications that lack the proper health risks to children, as well as sleeping mats previously banned by the FDA, according to a...Technologyread more
The recession obsession has captivated Wall Street, and experts are seeking stocks that can shield investors from the potential pain.Trading Nationread more
Google on Friday released a new set of community guidelines that are meant to crack down on what employees can say inside the company.Technologyread more
The idea came up as the White House brainstorms on ways to avoid a preelection economic slowdown, The Washington Post reports.US Economyread more
* Bayer's Vitrakvi wins EMA recommendation
If approved, would be EU debut for 'tumor-agnostic' approach
* Vitrakvi is high-precision genetic drug for cancer (Releads, adds U.S. debut, Bayer quote)
By Pushkala Aripaka and Ludwig Burger
July 26 (Reuters) - Europe's drug regulator has recommended approving Bayer's Vitrakvi, putting the medicine on track to become the first in Europe to tackle tumors with a specific genetic mutation regardless of where in the body the disease started.
The drug is being recommended for adults and children with difficult to treat forms of cancer that are driven by a rare genetic mutation known as NTRK gene fusion, the European Medicines Agency (EMA) said http://bit.ly/2Mi6s5o on Friday.
The European Commission has the final word on drug approvals but it generally follows EMA's recommendation within a couple of months.
The EMA endorsement marks a boost for the German company's drug development pipeline, which many analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.
The concept of a cancer drug's use based on genetic growth drivers and not on the tumor's location in the body received its first regulatory go-ahead in the United States in 2017.
At the time, it was Merck & Co's immunotherapy Keytruda that won approval from the U.S. Food and Drug Administration for this treatment approach, which is also known as tumor-agnostic.
The highly targeted approach has been shown to fight back advanced disease but only very rare genetic triggers have been pursued by drugmakers so far.
NTRK fusions, for instance, trigger cancer growth only in about 0.5 to 1.0% of solid tumors. Identifying those patients requires advanced diagnostic tools that are still being fine-tuned or - if available - have yet to win wide-spread use among oncologists.
"As researchers learn more about tumor genomics, it becomes all the more important to ensure broad access to genomic testing to allow patients that have the potential to benefit from precision medicines to be identified and treated," Scott Fields, Bayer's head of oncology development, said in a statement.
Bayer earlier this year took full control of Vitrakvi in a deal with Eli Lilly's Loxo Oncology, and the European thumbs-up follows U.S. regulatory approval in November.
The company's stock has slumped amid lawsuits over its Roundup weed killer, which it acquired after it bought U.S. seed company Monsanto.
Bayer clinched the initial Loxo deal for Vitrakvi, also known as larotrectinib, in November 2017.
(Editing by Saumyadeb Chakrabarty and Emelia Sithole-Matarise)